Hims & Hers Earnings Preview: Branded GLP-1 Pivot Faces First Test

What happened

Hims & Hers Health is set to report Q1 2026 results on May 11, with the market focused on whether its pivot from compounded to branded GLP-1 drugs (via the Novo Nordisk partnership) is sustaining revenue growth and gross margins. The Zacks article notes that Labs and branded weight loss medications could support results, but higher costs and ongoing regulatory scrutiny remain headwinds. The DeepValue Master Report rates the stock a WAIT, citing a 46.3x P/E and unresolved FDA/DOJ enforcement risks, compounded by a recent CEO share gift that raises governance questions. Gross margin has already compressed to 72% in Q4 2025, and the Q1 print will reveal if branded conversion and the weight-loss membership can preserve unit economics. Any signs of regulatory escalation or margin erosion could trigger a re-rating, while clarity on the ramp of branded GLP-1s and stable margins would support the current narrative.

Implication

Investors should wait for Q1 results before adjusting positions. The stock remains highly dependent on execution of the Novo partnership and avoidance of FDA/DOJ action. If gross margin stabilizes near 72% and branded GLP-1 adoption accelerates, the attractive entry point may be in the $22 area. However, the current price of $26.30 offers no margin of safety given net debt/EBITDA of 6.5x and unresolved legal risks. A disciplined approach is to trim above $32 and look to add on any regulatory-driven pullback below $22.

Thesis delta

The pre-earnings thesis remains WAIT, but the Q1 report is the pivotal catalyst that will either confirm the branded pivot is economically viable or expose continued margin pressure from the transition. The key now is not narrative but hard numbers on branded GLP-1 mix, subscriber retention, and gross margin trajectory. If the numbers disappoint, the stock could test its bear-case value of $18; if they impress, a run to $32+ is possible. The base case (50% probability) is $28, but the range of outcomes is wide given binary regulatory risks.